# Challenge II Phase 4: Pandemic Response Pipeline

**Date:** 2026-02-27 20:47 UTC
**Author:** Bradly Biron Baker Adams
**Pipeline Time:** 23.4 seconds

## 48-Hour Response Simulation

| Hour | Action | Status |
|------|--------|--------|
| 0 | Structure ingestion (PDB/CryoEM/AlphaFold) | ✓ |
| 1 | Energy field computation (6 probes, QTT) | ✓ |
| 4 | 2,000 candidates assembled | ✓ |
| 8 | Tox screening (8 panels) | ✓ |
| 12 | Synthesis feasibility (BRICS + BB check) | ✓ |
| 24 | Batch docking and scoring | ✓ |
| 48 | Top candidates with synthesis routes | ✓ |

## Target Summary

| Pathogen | Protein | Threat | Pocket | Scored | Best E | Routes |
|----------|---------|--------|--------|--------|--------|--------|
| SARS-CoV-2 | Main Protease (Mpro) | active | 142 | 18 | -9.21 | 18 |
| SARS-CoV-2 | Papain-Like Protease (PLpro) | active | 156 | 18 | 2067.22 | 18 |
| SARS-CoV-2 | RBD-ACE2 Interface | active | 152 | 18 | 4201.40 | 18 |
| Influenza H5N1 | Neuraminidase | emerging | 158 | 18 | 9.25 | 18 |
| Zika Virus | NS3 Protease | emerging | 149 | 18 | 1797.25 | 18 |
| Dengue Virus | NS3 Helicase | preparedness | 177 | 18 | 125.46 | 18 |
| HIV-1 | HIV-1 Protease | preparedness | 161 | 18 | 2882.60 | 18 |

### SARS-CoV-2 — Main Protease (Mpro)

| Rank | SMILES | E (kcal/mol) | Steps | BB Coverage |
|------|--------|--------------|-------|-------------|
| 1 | `COc1ccc2ncnc(Br)c2c1` | -9.21 | 3 | 100% |
| 2 | `c1ccc2sc(N3CCOCC3)nc2c1` | -2.47 | 3 | 100% |
| 3 | `O=C(Nc1cccc(Cl)c1)C1CCC(O)C1` | 18.28 | 5 | 100% |
| 4 | `COc1cc2ncnc(N(C)C)c2cc1OC` | 67.09 | 4 | 100% |
| 5 | `COc1cc2ncnc(S(C)(=O)=O)c2cc1OC` | 68.51 | 3 | 100% |
| 6 | `COc1cc2ncnc(Br)c2cc1OC` | 82.34 | 3 | 100% |
| 7 | `COc1cc2ncnc(C(F)(F)F)c2cc1OC` | 93.89 | 4 | 100% |
| 8 | `CCNc1ncnc2cc(OC)c(OC)cc12` | 97.05 | 5 | 100% |
| 9 | `CS(=O)(=O)c1ncnc2cc(Cl)ccc12` | 130.00 | 1 | 100% |
| 10 | `CCOc1ncnc2cc(OC)c(OC)cc12` | 171.56 | 5 | 100% |

### SARS-CoV-2 — Papain-Like Protease (PLpro)

| Rank | SMILES | E (kcal/mol) | Steps | BB Coverage |
|------|--------|--------------|-------|-------------|
| 1 | `COc1cc2ncnc(Br)c2cc1OC` | 2067.22 | 3 | 100% |
| 2 | `CS(=O)(=O)Nc1ncnc2cc(Cl)ccc12` | 2188.76 | 4 | 100% |
| 3 | `COc1ccc2ncnc(Br)c2c1` | 2215.20 | 3 | 100% |
| 4 | `O=C(Nc1ccc(F)cc1)C1CCC(O)C1` | 2839.08 | 5 | 100% |
| 5 | `COc1cc2ncnc(C(F)(F)F)c2cc1OC` | 2971.78 | 4 | 100% |
| 6 | `CS(=O)(=O)c1ncnc2cc(Cl)ccc12` | 3128.65 | 1 | 100% |
| 7 | `COc1cc2ncnc(NC(C)=O)c2cc1OC` | 3170.05 | 5 | 100% |
| 8 | `O=C(Nc1cccc(Cl)c1)C1CCC(O)C1` | 3255.28 | 5 | 100% |
| 9 | `c1ccc2sc(N3CCOCC3)nc2c1` | 3422.26 | 3 | 100% |
| 10 | `COc1ccc(NC(=O)C2CCC(O)C2)cc1` | 3846.62 | 6 | 100% |

### SARS-CoV-2 — RBD-ACE2 Interface

| Rank | SMILES | E (kcal/mol) | Steps | BB Coverage |
|------|--------|--------------|-------|-------------|
| 1 | `COc1ccc2ncnc(Br)c2c1` | 4201.40 | 3 | 100% |
| 2 | `CS(=O)(=O)c1ncnc2cc(Cl)ccc12` | 4257.23 | 1 | 100% |
| 3 | `COc1cc2ncnc(Br)c2cc1OC` | 4378.24 | 3 | 100% |
| 4 | `COc1cc2ncnc(C(F)(F)F)c2cc1OC` | 4380.40 | 4 | 100% |
| 5 | `O=C(Nc1cccc(Cl)c1)C1CCC(O)C1` | 4821.30 | 5 | 100% |
| 6 | `c1ccc2sc(N3CCOCC3)nc2c1` | 4939.73 | 3 | 100% |
| 7 | `CN1CCN(c2nc3ccccc3s2)CC1` | 4945.75 | 3 | 100% |
| 8 | `CCOc1ncnc2cc(OC)c(OC)cc12` | 5270.70 | 5 | 100% |
| 9 | `CCNc1ncnc2cc(OC)c(OC)cc12` | 5366.66 | 5 | 100% |
| 10 | `CS(=O)(=O)Nc1ncnc2cc(Cl)ccc12` | 5449.91 | 4 | 100% |

### Influenza H5N1 — Neuraminidase

| Rank | SMILES | E (kcal/mol) | Steps | BB Coverage |
|------|--------|--------------|-------|-------------|
| 1 | `CN1CCN(c2nc3ccccc3s2)CC1` | 9.25 | 3 | 100% |
| 2 | `COc1ccc2ncnc(Br)c2c1` | 65.36 | 3 | 100% |
| 3 | `CS(=O)(=O)c1ncnc2cc(Cl)ccc12` | 94.89 | 1 | 100% |
| 4 | `COc1ccc(NC(=O)C2CCC(O)C2)cc1` | 156.33 | 6 | 100% |
| 5 | `COc1cc2ncnc(C(F)(F)F)c2cc1OC` | 163.55 | 4 | 100% |
| 6 | `COc1cc2ncnc(Br)c2cc1OC` | 301.57 | 3 | 100% |
| 7 | `COc1cc2ncnc(S(C)(=O)=O)c2cc1OC` | 312.76 | 3 | 100% |
| 8 | `c1ccc2sc(N3CCOCC3)nc2c1` | 328.69 | 3 | 100% |
| 9 | `COc1cc2ncnc(NC(C)=O)c2cc1OC` | 499.38 | 5 | 100% |
| 10 | `COc1cc2ncnc(N(C)C)c2cc1OC` | 587.88 | 4 | 100% |

### Zika Virus — NS3 Protease

| Rank | SMILES | E (kcal/mol) | Steps | BB Coverage |
|------|--------|--------------|-------|-------------|
| 1 | `CS(=O)(=O)c1ncnc2cc(Cl)ccc12` | 1797.25 | 1 | 100% |
| 2 | `COc1cc2ncnc(Br)c2cc1OC` | 2122.23 | 3 | 100% |
| 3 | `COc1ccc2ncnc(Br)c2c1` | 2362.69 | 3 | 100% |
| 4 | `CS(=O)(=O)Nc1ncnc2cc(Cl)ccc12` | 2700.34 | 4 | 100% |
| 5 | `c1ccc2sc(N3CCOCC3)nc2c1` | 3016.29 | 3 | 100% |
| 6 | `O=C(Nc1cccc(Cl)c1)C1CCC(O)C1` | 3020.57 | 5 | 100% |
| 7 | `COc1cc2ncnc(C(F)(F)F)c2cc1OC` | 3113.52 | 4 | 100% |
| 8 | `COc1cc2ncnc(NC(C)C)c2cc1OC` | 3116.23 | 5 | 100% |
| 9 | `O=C(Nc1ccc(F)cc1)C1CCC(O)C1` | 3218.85 | 5 | 100% |
| 10 | `COc1cc2ncnc(S(C)(=O)=O)c2cc1OC` | 3419.44 | 3 | 100% |

### Dengue Virus — NS3 Helicase

| Rank | SMILES | E (kcal/mol) | Steps | BB Coverage |
|------|--------|--------------|-------|-------------|
| 1 | `COc1ccc2ncnc(Br)c2c1` | 125.46 | 3 | 100% |
| 2 | `c1ccc2sc(N3CCOCC3)nc2c1` | 159.53 | 3 | 100% |
| 3 | `CS(=O)(=O)c1ncnc2cc(Cl)ccc12` | 260.66 | 1 | 100% |
| 4 | `COc1cc2ncnc(NC(C)C)c2cc1OC` | 332.67 | 5 | 100% |
| 5 | `O=C(Nc1ccc(F)cc1)C1CCC(O)C1` | 336.97 | 5 | 100% |
| 6 | `COc1cc2ncnc(C(F)(F)F)c2cc1OC` | 612.49 | 4 | 100% |
| 7 | `COc1ccc(NC(=O)C2CCC(O)C2)cc1` | 652.09 | 6 | 100% |
| 8 | `CCOc1ncnc2cc(OC)c(OC)cc12` | 726.80 | 5 | 100% |
| 9 | `CCNc1ncnc2cc(OC)c(OC)cc12` | 769.78 | 5 | 100% |
| 10 | `COc1cc2ncnc(NS(C)(=O)=O)c2cc1OC` | 806.66 | 5 | 100% |

### HIV-1 — HIV-1 Protease

| Rank | SMILES | E (kcal/mol) | Steps | BB Coverage |
|------|--------|--------------|-------|-------------|
| 1 | `COc1ccc2ncnc(Br)c2c1` | 2882.60 | 3 | 100% |
| 2 | `COc1cc2ncnc(Br)c2cc1OC` | 2893.54 | 3 | 100% |
| 3 | `CS(=O)(=O)c1ncnc2cc(Cl)ccc12` | 3120.77 | 1 | 100% |
| 4 | `COc1cc2ncnc(C(F)(F)F)c2cc1OC` | 3233.90 | 4 | 100% |
| 5 | `c1ccc2sc(N3CCOCC3)nc2c1` | 4168.98 | 3 | 100% |
| 6 | `O=C(Nc1cccc(Cl)c1)C1CCC(O)C1` | 4377.32 | 5 | 100% |
| 7 | `COc1cc2ncnc(S(C)(=O)=O)c2cc1OC` | 4465.60 | 3 | 100% |
| 8 | `CS(=O)(=O)Nc1ncnc2cc(Cl)ccc12` | 4668.75 | 4 | 100% |
| 9 | `COc1cc2ncnc(N(C)C)c2cc1OC` | 4810.54 | 4 | 100% |
| 10 | `COc1cc2ncnc(NC(C)=O)c2cc1OC` | 4851.35 | 5 | 100% |

## Exit Criteria

| Criterion | Value | Threshold | Status |
|-----------|-------|-----------|--------|
| Targets ≥ 3 | 7 | 3 | ✓ PASS |
| Targets with ≥10 routes | 7 | 3 | ✓ PASS |
| Timeline simulation | Complete | — | ✓ PASS |
| Output package | Generated | — | ✓ PASS |

**Overall: ✓ PASS**
